Group 1 - The core point of the article highlights the recent stock performance of Green Leaf Pharmaceutical, which saw a decline of 2.12% to 3.69 CNY per share with a trading volume of 304 million CNY [1] - Green Leaf Pharmaceutical operates in four major therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, with a product portfolio of over 30 products available in more than 80 countries and regions [1] - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1] Group 2 - The company is set to disclose its interim report for the fiscal year 2025 on August 28 [1]

本次交易涉及其他关联方：Ong Tiong Sin、RRJ Capital IV Ltd、RRJ Capital Master Fund IV,L.P.。 香港联交所最新资料显示，8月13日，Kale Asset Holding Ltd减持绿叶制药(02186)1124.6万股，平均每股 作价3.763港元，总金额约为4231.87万港元。减持后最新持股数目约为3亿股，最新持股比例为7.93%。 ...

智通财经APP获悉，香港联交所最新资料显示，8月13日，Kale Asset Holding Ltd减持绿叶制药 (02186)1124.6万股，平均每股作价3.763港元，总金额约为4231.87万港元。减持后最新持股数目约为3亿 股，最新持股比例为7.93%。 本次交易涉及其他关联方：Ong Tiong Sin、RRJ Capital IV Ltd、RRJ Capital Master Fund IV, L.P.。 ...

Group 1 - The top three companies with the highest short positions as of August 15 are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 14.92%, 14.41%, and 13.40% respectively [1][2] - The companies with the largest absolute increase in short positions are Heng Rui Medicine (01276), Yao Cai Securities (01428), and Modern Animal Husbandry (01117), with increases of 2.49%, 1.34%, and 1.31% respectively [1][2] - The companies with the largest absolute decrease in short positions are Ganfeng Lithium (01772), WuXi AppTec (02359), and Fourth Paradigm (06682), with decreases of -2.98%, -2.67%, and -2.28% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Ping An Insurance (02318) at 12.46%, Green Leaf Pharmaceutical (02186) at 12.36%, and Vanke Enterprises (02202) at 12.13% [2] - The companies with the most significant increases in short ratios include Heng Rui Medicine (01276) from 0.51% to 2.99%, Yao Cai Securities (01428) from 3.47% to 4.81%, and Modern Animal Husbandry (01117) from 4.74% to 6.05% [2] - The companies with the most significant decreases in short ratios include Ganfeng Lithium (01772) from 13.32% to 10.34%, WuXi AppTec (02359) from 17.59% to 14.92%, and Fourth Paradigm (06682) from 2.74% to 0.46% [2][3]

Core Viewpoint - Jiangsu Enhua Pharmaceutical Co., Ltd. has had its application for the market launch of Oxycodone Naloxone Extended-Release Tablets accepted, indicating a significant step in the competitive landscape of pain management medications in China [1][3]. Group 1: Product Overview - Oxycodone Naloxone Extended-Release Tablets are a combination of the potent opioid agonist oxycodone and the opioid antagonist naloxone, designed for treating moderate to severe chronic pain that is not effectively managed by non-opioid medications [3][5]. - The total sales of oxycodone in Chinese hospitals reached CNY 165.52 billion, with a projected sales increase of 13.92% to CNY 17.54 billion in 2024, highlighting its dominant position in the moderate to severe pain treatment market [3][5]. Group 2: Market Dynamics - The market for Oxycodone Naloxone Extended-Release Tablets is expected to be substantial, with potential to disrupt the current market structure dominated by NAPP Pharmaceuticals, which holds a 99.44% market share of oxycodone extended-release tablets in China [5][7]. - The first application for this product was submitted by Green Leaf Pharmaceutical in January 2022 but was not approved, indicating the competitive challenges in the market [7][11]. Group 3: Regulatory and Competitive Landscape - The product has been classified as a Category 4 generic drug, with the application officially accepted on August 19, 2025, marking it as the first approved domestic version of Oxycodone Naloxone Extended-Release Tablets [1][9]. - The high technical barriers and complex patent challenges associated with the product have limited the number of domestic generic manufacturers, with the core patent set to expire in August 2027 [12][17]. Group 4: Industry Trends - The increasing focus on high-barrier products and the shift from simple generics to innovative approaches in the extended-release formulation space reflect a deep adjustment in the industry landscape, driven by heightened competition and the need for technological advancements [17].

绿叶制药(02186)发布公告，于2025年8月20日，因转换可转换债券而发行5291.9万股。 ...

智通财经APP讯，绿叶制药(02186)发布公告，于2025年8月20日，因转换可转换债券而发行5291.9万 股。 ...

格隆汇8月20日丨绿叶制药(02186.HK)发布公告，2025年8月20日，按每股兑换价港币3.672元兑换由公 司发行的2025年到期的2500万美元5.85%利率可转换债券而发行5291.94万股普通股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 02186 ...

Core Viewpoint - Green Leaf Pharmaceutical experienced a 4.02% decline in stock price, closing at 3.82 CNY per share with a trading volume of 302 million CNY on August 20 [1] Company Overview - Green Leaf Pharmaceutical Group Limited focuses on the development, production, promotion, and sales of innovative drugs in four major therapeutic areas: oncology, central nervous system, cardiovascular system, and digestive and metabolic diseases [1] - The company has a product portfolio of over 30 products, distributed across more than 80 countries and regions globally [1] Operational Highlights - In 2021, the company's product sales reached all 30 provinces, autonomous regions, and municipalities in China, supported by approximately 1,000 sales and marketing personnel and a network of about 1,780 distributors [1] - The products are sold to over 19,330 hospitals, with international market coverage extending to 80 countries or regions [1] Financial Performance - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1]